IceCure Medical Ltd (NASDAQ:ICCM - Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 802,800 shares, a decline of 9.2% from the January 15th total of 883,900 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily volume of 607,200 shares, the days-to-cover ratio is currently 1.3 days.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $2.50 target price on shares of IceCure Medical in a research report on Wednesday, November 27th. Alliance Global Partners upgraded shares of IceCure Medical to a "strong-buy" rating in a report on Friday, November 1st.
View Our Latest Report on ICCM
IceCure Medical Stock Down 6.0 %
Shares of ICCM stock traded down $0.09 on Friday, hitting $1.41. The company's stock had a trading volume of 448,720 shares, compared to its average volume of 414,159. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.27. IceCure Medical has a fifty-two week low of $0.48 and a fifty-two week high of $1.66. The firm's fifty day moving average price is $1.24 and its 200-day moving average price is $0.87. The stock has a market capitalization of $78.26 million, a price-to-earnings ratio of -4.86 and a beta of 0.40.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last posted its earnings results on Tuesday, November 26th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. Research analysts anticipate that IceCure Medical will post -0.28 EPS for the current year.
Institutional Trading of IceCure Medical
An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC lifted its holdings in shares of IceCure Medical Ltd (NASDAQ:ICCM - Free Report) by 58.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,453 shares of the company's stock after buying an additional 14,893 shares during the quarter. Geode Capital Management LLC owned about 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors.
IceCure Medical Company Profile
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Read More
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
